BENTLEY-SYSTEMS
7.4.2022 22:03:11 CEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced it has acquired Watertown, Massachusetts-based ADINA R & D Inc., a leading developer of finite element analysis software applications used in a comprehensively diverse range of engineering fields (adina.com ). ADINA was founded in 1986 by Dr. Klaus-Jürgen Bathe, professor of mechanical engineering at the Massachusetts Institute of Technology and a world-renowned leader in the field of finite element analysis and its applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406006024/en/
Civil, structural, and mechanical engineers choose ADINA software for its authoritative veracity, including in analysis of buildings, bridges, stadiums, pressure vessels, dams, and tunnels. By virtue of the ADINA System’s integral robustness across disciplines, materials, and simulation domains (structures, mechanical, fluids, thermal, electromagnetic, and multi-physics), engineers use it to perform comprehensive safety and performance studies where reliability and resilience are of critical importance.
With infrastructure digital twins, users can simulate the complete behavior of structures to create confidence in designs that are much safer and more cost-effective than those merely analyzed to meet prescribed code standards. Of particular importance for infrastructure resilience, ADINA will also be applied within digital twins of existing infrastructure assets, now made practical by the Bentley iTwin platform, to simulate their responses and vulnerabilities to stresses so extreme that nonlinear effects must be considered—caused (for instance) by seismic, wind, flood, pressure, thermal, collision, or blast forces.
The ADINA System’s nonlinear simulation capabilities will in turn become directly accessible, through convenient technical and commercial integration, to users of Bentley Systems’ uniquely comprehensive modeling and simulation software portfolio for infrastructure engineering. As the ADINA System’s nonlinear extensions are introduced to complement these existing physical simulation applications—currently spanning STAAD, RAM, SACS, MOSES, AutoPIPE, PLAXIS, LEAP, RM, LARS, SPIDA, and PLS—the scope of mainstream simulation underlying the engineering of infrastructure resilience will be valuably enhanced. ADINA’s advantages also include advanced dynamics, 3D solid FEM, buckling, substructuring, and advanced meshing for critical joints and sections.
“Incorporating ADINA and its creators is very exciting for all of our engineering simulation teams, as it will also be for existing and new users,” said Raoul Karp, vice president, engineering simulation at Bentley Systems. “Dr. Bathe literally wrote the book on advancing finite element simulations, and the ADINA System provides the reference for benchmarking all other disparate analysis approaches. We will now be able to extend nonlinear realism across all of our infrastructure digital twin simulation offerings.”
Founder of ADINA Dr. K.J. Bathe, who will remain as a technical advisor, said, “My colleagues and I are proud to be joining Bentley Systems’ broad and deep simulation team. Our aim in the development of ADINA has always been to provide a most reliable and efficient analysis tool to scientists and engineers, and it is wonderful that with Bentley, ADINA will now be used and further developed with great potential for solving the varied and interrelated challenges of infrastructure resilience.”
Image 1
:
Caption: The frictional sliding of a prestressed concrete bridge girder can be studied with ADINA technology.
Image 2
:
Caption: Collapse analysis of pressurized pipe can be performed with ADINA software.
Image 3
:
Caption: Simulation of a pipe break in a nuclear reactor using ADINA technology.
Image 4
:
Caption: Sloshing of an oil tank with the base subjected to horizontal ground motion with ADINA software.
##
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software
company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation
-based applications for modeling and simulation, ProjectWise
for project delivery, AssetWise
for asset and network performance, Seequent’s leading geoprofessional software portfolio, and the iTwin
platform for infrastructure digital twins. Bentley Systems employs more than 4,500 colleagues and generates annual revenues of approximately $1 billion in 186 countries.
www.bentley.com
© 2022 Bentley Systems, Incorporated. Bentley, the Bentley logo, ADINA, AssetWise, AutoPIPE, iTwin, LARS, LEAP, SPIDA, MicroStation, MOSES, PLAXIS, PLS, ProjectWise, RAM, RM, SACS, Seequent, and STAAD are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406006024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
